{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:30:20Z","timestamp":1792737020074,"version":"4.5.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2,20]]},"DOI":"10.1097\/qad.0b013e328323da60","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T15:03:14Z","timestamp":1242918194000},"page":"455-460","source":"Crossref","is-referenced-by-count":65,"title":["Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies"],"prefix":"10.1097","volume":"23","author":[{"given":"Filippo","family":"Canducci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Sampaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Marinozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Boeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Lazzarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00003495-200868010-00009","article-title":"Raltegravir","volume":"68","author":"Croxtall","year":"2008","journal-title":"Drugs"},{"key":"R2-3-20210130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-3-20210130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"R4-3-20210130","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"R5-3-20210130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/apc.2007.0136","article-title":"Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection","volume":"22","author":"Moyle","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"R6-3-20210130","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/589289","article-title":"Reviews of antiinfective agents: maraviroc \u2013 the first of a new class of antiretroviral agents","volume":"47","author":"MacArthur","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R7-3-20210130","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jac\/dkn248","article-title":"Shifting paradigms: the resistance profile of etravirine","volume":"62","author":"Geretti","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R8-3-20210130","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1128\/AAC.48.9.3253-3259.2004","article-title":"Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment","volume":"48","author":"Menzo","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-3-20210130","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1089\/088922203771881257","article-title":"Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure","volume":"19","author":"Boeri","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R10-3-20210130","first-page":"105","article-title":"Phylogenetic internal control for HIV-1 genotypic antiretroviral testing","volume":"27","author":"Boeri","year":"2004","journal-title":"New Microbiol"},{"key":"R11-3-20210130","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-3-20210130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350701200411","article-title":"Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance","volume":"12","author":"Lataillade","year":"2007","journal-title":"Antivir Ther"},{"key":"R13-3-20210130","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1128\/JVI.02660-07","article-title":"Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing","volume":"82","author":"Salazar-Gonzalez","year":"2008","journal-title":"J Virol"},{"key":"R14-3-20210130","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1128\/JVI.74.10.4795-4806.2000","article-title":"Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells","volume":"74","author":"Tsurutani","year":"2000","journal-title":"J Virol"},{"key":"R15-3-20210130","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1128\/AAC.00911-07","article-title":"Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137","volume":"52","author":"Hombrouck","year":"2008","journal-title":"Antimicrob Agents Chemother"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-200902200-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T16:44:16Z","timestamp":1739119456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-200902200-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,20]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328323da60","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2,20]]}}}